Clinical Validation of a Capillary Blood Home-Based Self-Sampling Technique for Monitoring of Infliximab, Vedolizumab, and C-Reactive Protein Concentrations in Patients With Inflammatory Bowel Disease

A finger prick-based capillary blood self-sampling technique was validated for home monitoring of infliximab, vedolizumab, and C-reactive protein concentrations in a population of patients with inflammatory bowel disease, who reported substantial support, tolerability, and practicality for the investigated technique. Background Therapeutic drug monitoring provides important guidance for treatment of patients with inflammatory bowel disease (IBD) and could help to early identify treatment failure. This study aimed to validate a finger prick-based capillary blood sampling technique to measure biological trough levels and C-reactive protein (CRP) and evaluate patient performance and -support. Methods In this prospective cohort study, patients with IBD receiving infliximab (IFX) or vedolizumab (VEDO) therapy performed finger prick-based capillary blood sampling at home. Additionally, blood was collected through routinely performed in-hospital venepuncture prior to biological infusion. IFX, VEDO, and CRP concentrations were measured by enzyme-linked immunosorbent assay. The concordance between methods was statistically evaluated and a survey was conducted to assess practicality and patient support. Results In total, 81 patients (46 IFX, 35 VEDO) were enrolled. Mean differences between both methods were 0.42 (95% confidence interval, -1.74 to 2.58) mu g/mL for IFX and 0.72 (95% confidence interval, -5.50 to 6.94) mu g/mL for VEDO. Passing-Bablok regressions demonstrated no evidence for systematic or proportional biases. Venous and capillary IFX (rho = 0.96, P < .001) and VEDO (rho = 0.97, P < .001) levels strongly correlated and showed high intermethod agreement (Cohen's kappa: IFX = 0.82; VEDO = 0.94). Similarly, venous and capillary CRP levels were strongly correlated (rho = 0.99, P < .001). Most patients (>95%) were able to successfully perform the self-sampling at home without prior instructions. Conclusions This study clinically validated a finger prick-based capillary blood self-sampling technique allowing concomitant home monitoring of biological levels and CRP for patients with IBD, who reported substantial support, tolerability, and practicality.

Automated summary

A finger prick-based capillary blood self-sampling technique was validated for monitoring infliximab, vedolizumab, and C-reactive protein concentrations in patients with inflammatory bowel disease. The technique received substantial support from patients and demonstrated good tolerability and practicality.